Boston, MA 10/14/2014 (wallstreetpr) – Dynavax Technologies Corporation (NASDAQ:DVAX) announced on 13th October that it had initiated phase 1/2 clinical trials of its drug candidate SD-101. The target drug is expected to treat “lymphoma.” The drug would be tested across multiple study centres and will be introduced into the patient intratumorally. The treatment would be running co-terminus with low dose radiation therapy. Company CEO Eddie Gray has indicated that the starting of the clinical trial is a important milestone since it demonstrates the maturity of its past few years drug development efforts. During the current testing cycle, nearly 25 patients who are suffering from B cell Lymphomas will be administered the test drug.
Drug maker Cesca Therapeutics Inc. (NASDAQ:KOOL) announced on 13th October that the firm had successfully bid for and has been awarded a new contract by Upstate Medical University. The contract involves providing a “cell storage, processing and consumables platform” to the Upstate Cord Blood Bank operated by the Upstate Medical University. Upstate Cord Blood Bank facility was recently set up at a cost of $15 million. It is located in New York. It will be collecting the “umbilical cord blood” which would be donated by concerned families. The cord blood would be used to further the development of “life-saving medical treatments and for medical research”. Cesca Therapeutics Inc. (NASDAQ:KOOL) Chief Executive Officer Matthew Plavan has described the deal as a key win for his company’s nascent cord blood business.
F5 Networks (NASDAQ:FFIV) announced on 13th October that it has secured an award which differentiates it as the “the industry’s top Web Application Firewall (WAF) vendor.” The recognition came its way after NSS Labs benchmarked all vendors in this space few months back. The firm’s “Application Security Manager™” has won the “recommended” status when compared against similar solutions from completion. The NSS report findings allows prospective buyers to compare technology before making their buying decision.
